Selegiline effects on cocaine-induced changes in medial temporal lobe metabolism and subjective ratings of euphoria

 Bartzokis G, Beckson M, Newton T, Mandelkern M,
Mintz J, Foster JA, Ling W, Bridge TP
Psychiatry Service,
Little Rock VA Medical Center,
AR 72114, USA.
Neuropsychopharmacology 1999 Jun; 20(6):582-90

ABSTRACT

To test the effect of selegiline, a specific monoamine oxidase B (MAO-B) inhibitor, on the cerebral metabolic and euphorigenic effects of cocaine in experienced users, eight cocaine-dependent (CD) subjects were evaluated using a within-subjects design. Each subject participated in two pairs of [F-18]-fluorodeoxyglucose (FDG)-positron emission tomography (PET) scans (baseline scan followed 24 h later by a second scan obtained in conjunction with a 40-mg cocaine infusion) performed before and after a 1-week period of daily treatment with 10 mg selegiline administered orally. The hippocampus and amygdala were evaluated because of their hypothesized involvement in the addiction process, and the thalamus was evaluated as a comparison region. Following 7 days of selegiline treatment, the magnitude of the subjective euphoria ("high") produced by cocaine infusion was reduced by 40% (cocaine by selegiline interaction F = 7.15, df = 1.21, p = .014). Selegiline treatment also altered glucose utilization (normalized against whole brain counts) in the two limbic regions, but not the thalamus. In the amygdala, the effects of cocaine differed, depending upon whether or not patients were being treated with selegiline (cocaine by selegiline interaction F = 4.67, df = 1,19.8, p = .043). A different effect was observed in the hippocampus, where selegiline treatment decreased metabolic activity irrespective of whether cocaine was given (main effect F = 7.70, df = 1.20, p = .012). The concomitant changes in both the subjective experience of the "high" and normalized amygdala glucose utilization after selegiline treatment, suggest that a relationship exists between cocaine-induced euphoria and limbic metabolism. The data suggest that selegiline may be a useful adjunct in the treatment of cocaine dependence.

Home | Order
 
  • Deprenyl   is an effective antidepressant
  • Deprenyl   in treatment-resistant older depressive patients
  • Deprenyl   + phenylalanine was beneficial in 90% of depression patients
  • Deprenyl   antidepressant effects are by means other than MAO-B inhibition
     Deprenyl   treated rats were much more sexually active
    Deprenyl       enhances sexual performance and longevity in rats
    Deprenyl   may delay the deterioration of neurons during aging
  • Deprenyl   the history of deprenyl
  • Deprenyl   decreases susceptibility to Parkinson's & Alzheimer's disease
  • Deprenyl   restores IGF-1 to youthful levels
  • Deprenyl   protects the vascular endothelium from beta amyloid plaque
  • Deprenyl   reduces cocaine "high"
  • Deprenyl   prolongs animal lifespan by reducing oxidative damage to the brain
  • Deprenyl   may be useful in the treatment of cocaine dependence
  • Deprenyl   increases the life span in Fischer rats
  • Deprenyl   effects on short term memory in young and aged dogs
  • Deprenyl   maintains sexual acitivity in old rats
  • Deprenyl   and Fluoxetine (Prozac) do not interact in combination
  • Deprenyl   prolongs life in elderly dogs
  • Deprenyl   has a cardiac neuroprotective effect
  • Deprenyl   reduces oxidative stress and increases free radical elimination

  • Deprenyl   responses of forebrain neurons to deprenyl

  • Deprenyl   Parkinson's and Alzheimer's patients need 10 mg of deprenyl daily

  • Deprenyl   inhibits tumor growth in rats with mammary tumors

  • Deprenyl   slows the decline of sexual and learning performances in rats

  • Deprenyl   is ten times stronger than methamphetamine as a catecholaminergic

  • Deprenyl   shows favorable results in Tourette's syndrome and narcolepsy

  • Deprenyl   treated rats lived beyond the known maximum lifespan

  • Deprenyl   protects cells from the DNA damage

  • Deprenyl   may protect neurons from ischemic or oxidative damage

  • Deprenyl   prolongs animal lifespan by reducing oxidative damage to the brain

  • Deprenyl   effects on cocaine-induced euphoria

  • Deprenyl   effects on response to experimental cocaine administration  

  • Deprenyl   Are metabolites of deprenyl useful or harmful?

  • Deprenyl   slows the progression of Parkinson's disease

  • Deprenyl   suppresses excitotoxic damage in Parkinson's disease

  • Deprenyl   effect of deprenyl on arm movement in early Parkinson's

  • Deprenyl   effect on cognitive functions in early Parkinson's 

  • Deprenyl   prolongs the life span of Parkinsonian patients significantly

  • Deprenyl   depression in Parkinson's disease

  • Deprenyl   increases the dopamine content of the nerve terminals in Parkinson's

  • Deprenyl   improves visuo-motor control in early Parkinsonism

  • Deprenyl   management of early Parkinson's disease

  • Deprenyl   delays the onset of disability in Parkinsonian patients

  • Deprenyl   and tocopherol antioxidative therapy of Parkinsonism

  • Deprenyl   slows the death of nigral neurons in Parkinson's disease

  • Deprenyl   + levodopa treated Parkinson's patients live longer

  • Deprenyl   stimulates biosynthesis of cytokines interleukin-1 & 6

  • Deprenyl   effect of MAO-B inhibitors on MPP+ toxicity

  • Deprenyl   modulates the activity of catecholamine-sensitive neurons

  • Deprenyl   improves the performance of patients with Alzheimer's disease

  • Deprenyl   MAO-B inhibitors in the treatment of Alzheimer's disease

  • Deprenyl   in the treatment of Alzheimer's disease

  • Deprenyl   stimulates biosynthesis of cytokines interleukin-1 & 6

  • Deprenyl   and age-related decline of the striatal dopaminergic system

  • Deprenyl   increases dopamine in the striatum of primates

  • Deprenyl   use in treatment-resistant elderly depression patients

  • Deprenyl   protects against neurotoxins

  • Deprenyl   effects during smoking and short-term abstinence